24 July 2018
Visiongain’ has launched a new pharma report Global Ophthalmic Drugs Market Forecast 2018-2028: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs
Ophthalmic pharmaceuticals are pharmaceutical agents used to treat eye diseases, such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, ocular allergies, infections, inflammatory conditions and dry eye. A specialist sector within the overall pharmaceutical industry, the ophthalmic drugs market is dominated by a relatively small number of companies. The market is relatively mature though with opportunities for growth in key therapeutic areas.
The lead analyst of the report commented “For many indications, the advantages of pharmaceutical treatment far outweigh the benefits offered by alternative treatments such as surgery. As glaucoma, retinal disorders, inflammatory conditions and moderate to severe dry eye require management by medical professionals, the preferred treatment will be largely guided by clinical considerations rather than competition between alternative treatments.
Gene therapies and other regenerative medicine approaches to ophthalmic diseases may become effective substitutes towards the end of the forecast period. The area of gene therapy is still in its infancy with only a handful of currently marketed products. There is much research interest in gene therapies for conditions such as Leber’s congenital amaurosis and retinitis pigmentosa.”
Leading companies featured in the report include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.